Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

The treatment was not recommended due to limited effectiveness and significant side effects.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Tofacitinib might be used to treat hair loss.

JAK inhibitors are effective treatments for alopecia areata.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Antifungal treatment reduced asthma exacerbations and corticosteroid use but its overall benefit is unclear.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.

Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.

A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Apremilast showed mixed results for treating severe alopecia areata.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.